BMY Bristol-Myers Squibb Company

Price (delayed)

$59.14

Market cap

$133.82B

P/E Ratio

92.41

Dividend/share

$1.76

EPS

$0.64

Enterprise value

$164.7B

Business Summary

Sector: Healthcare
Industry: Drug Manufacturers - General
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Highlights

The company's revenue rose by 33% YoY and by 19% QoQ
Bristol Myers Squibb Co's gross profit has increased by 27% YoY and by 17% from the previous quarter
The quick ratio has decreased by 16% YoY but it has increased by 10% QoQ
The stock's price to earnings (P/E) is 154% more than its last 4 quarters average of 36.4 and 71% more than its 5-year quarterly average of 54.2
The net income has dropped by 82% year-on-year and by 72% since the previous quarter

Key stats

Shares outstanding
2.26B
Market cap
$133.82B
Enterprise value
$164.7B
EBIT
$2.67B
EBITDA
$6.72B
Price to earnings (P/E)
92.41
Price to book (P/B)
2.67
Price to sales (P/S)
4.31
EV/EBIT
61.76
EV/EBITDA
24.51
Net debt/EBITDA
4.6
EV/Sales
5.31
EBITDA margin
21.7%
Gross margin
68.1%
Net margin
3.1%
Operating margin
8.7%
Return on assets
1%
Return on equity
2.8%
Return on invested capital
5.8%
Return on capital employed
2.4%
Return on sales
8.6%
Debt to equity
0.94
Free cash flow
$9.75B
Free cash flow per share
$4.32
Book value per share
$22.11
Revenue per share
$13.73
TBVPS
$20.01
Current ratio
1.66
Quick ratio
1.38
Working capital
$12.62B
Dividend yield
2.98%
DPS
$1.76
Payout ratio
275%

BMY stock price

Financial performance

BMY's net margin has dropped by 86% year-on-year and by 77% since the previous quarter
The net income has dropped by 82% year-on-year and by 72% since the previous quarter
The operating margin has dropped by 67% year-on-year and by 54% since the previous quarter
The operating income has dropped by 56% year-on-year and by 46% since the previous quarter

Valuation

Price to earnings (P/E)
Current price to earnings (P/E):
92.41
The stock's price to earnings (P/E) is 154% more than its last 4 quarters average of 36.4 and 71% more than its 5-year quarterly average of 54.2
Bristol Myers Squibb Co's EPS has shrunk by 80% YoY and by 68% QoQ
Price to book (P/B)
Current price to book (P/B):
2.67
BMY's P/B is 57% below its 5-year quarterly average of 6.2 and 24% below its last 4 quarters average of 3.5
Bristol Myers Squibb Co's equity has decreased by 3.3% from the previous quarter
Price to sales (P/S)
Current price to sales (P/S):
4.31
The company's revenue rose by 33% YoY and by 19% QoQ
The price to sales (P/S) is 17% more than the last 4 quarters average of 3.7 but 10% less than the 5-year quarterly average of 4.8

Efficiency

Bristol Myers Squibb Co's ROA has plunged by 93% YoY and by 80% from the previous quarter
The ROE has plunged by 93% YoY and by 80% from the previous quarter
BMY's return on invested capital has dropped by 84% year-on-year and by 58% since the previous quarter
Bristol Myers Squibb Co's return on sales has shrunk by 67% YoY and by 55% QoQ

Dividends

DPS
$1.76
Dividend yield
2.98%
Payout ratio
275%

Recent dividends

Financial health

Assets vs liabilities
BMY's total assets is 63% greater than its total liabilities
The quick ratio has decreased by 16% YoY but it has increased by 10% QoQ
Bristol Myers Squibb Co's current ratio has decreased by 14% YoY but it has increased by 3.8% from the previous quarter
Debt vs equity
BMY's debt is 6% smaller than its equity
The company's debt to equity has surged by 135% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.